Malignant Pleural Mesothelioma: From Pathophysiology to Novel Therapeutic Approaches
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: 30 April 2025 | Viewed by 245
Special Issue Editor
Special Issue Information
Dear Colleagues,
Mesothelioma is a rare, but aggressive cancer type, originating from mesothelium tissues covering the lungs (pleura), heart (pericardium), abdomen (peritoneum) and testes (tunicae testis). However, 90% of mesothelioma cases are of malignant pleural mesothelioma (MPM), which is usually associated with exposure to asbestos. MPM involves tumour suppressor gene mutation instead of oncogenes, so targeted therapies are rarely applied. In the last two decades, chemotherapy has been the only fist-line treatment for unresectable MPM. Immunotherapy was approved by FDA in 2020, but only a small population of patients benefit from it. Further studies are needed to understand this disease and develop novel therapeutic approaches. In this collection, we aim to include research focused on the histological, molecular, and biological mechanisms of MPM and pleural effusion, the potential biomarkers for different treatment strategies, advanced diagnostic techniques, novel therapies for MPM (targeted, metabolomic, and immune therapies), and promising models of MPM (organoids, tissue slices, and mouse models).
Dr. Yanyun Gao
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- malignant pleural mesothelioma
- diagnosis
- molecular subtypes
- chemotherapy
- target therapy
- MPM metabolism
- biomarkers
- immunotherapy
- preclinical models for MPM
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
